Programmed Death-Ligand 1, PDL1, PD-L1: 1366 Clinical Trials, Page 1 of 137

1 2 3 4 5 …10 15 20 … »Last Page »

Hide Studies Not Open or Pending

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Condition(s):Ovarian Cancer; Fallopian Tube Cancer; Peritoneal NeoplasmsLast Updated:April 19, 2021Recruiting

Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:October 5, 2020Active, not recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Condition(s):Squamous Cell Carcinoma of Head and NeckLast Updated:April 1, 2021Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Condition(s):Breast CancerLast Updated:December 16, 2020Completed

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Condition(s):Advanced/Metastatic Gastroesophageal AdenocarcinomaLast Updated:April 12, 2021Recruiting

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Condition(s):Ovarian NeoplasmsLast Updated:February 23, 2021Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Condition(s):Triple Negative Breast Cancer (TNBC)Last Updated:December 17, 2020Active, not recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:March 29, 2021Recruiting

Vibostolimab (MK-7684) With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)

Condition(s):Lung Neoplasms; Non-Small-Cell Lung CarcinomaLast Updated:March 11, 2021Not yet recruiting

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)

Condition(s):Esophageal NeoplasmsLast Updated:April 19, 2021Active, not recruiting

1 2 3 4 5 …10 15 20 … »Last Page »

Trial Bulletin .com

Clinical Trials by Category

Clinical Trials Alphabetically

About

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.